Focused on the Future

Our robust pipeline is strategically diversified across several therapeutic areas in ophthalmology that represent attractive market opportunities and continued growth potential. Our product candidates are engineered to address specific therapeutic needs across ocular surface, anterior segment and posterior segment diseases, including the leading causes of blindness. With an aging population, there is a clear growing need for these types of innovative ocular therapies that can enhance the overall patient and physician experience.

Product/Program Disease State Description Preclinical Phase 1 Phase 2 Phase 3 Regulatory Approval
Approved Product
ReSure Cataract incision closure Ocular sealant
Late Stage Product Candidates
Dextenza Post-surgical pain and inflammation Intracanalicular insert
OTX-DP (dexamethasone insert) Allergic conjunctivitis Intracanalicular insert
OTX-TP (travoprost insert) Glaucoma, Ocular Hypertension Intracanalicular insert
Early Stage Product Candidates
OTX-TIC (travoprost implant) Glaucoma, Ocular Hypertension Intracameral Injection
OTX-TKI"tyrosine kinase inhibitor" implant Wet AMD, DME, RVO* Intravitreal Injection
OTX-IVT+ "anti-VEGF antibody" implant Wet AMD, DME, RVO* Intravitreal Injection

* Wet Age-related Macular Degeneration (Wet AMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
+ In Partnership with REGENERON